Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen
The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
During 1985–1990 the U.S. National Cancer Institute (NCI) phased out its murine leukemia P388 anticancer drug screening program and developed as the replacement a new in vitro primary screen based upon a diverse panel of human tumor cell lines. For each substance tested, the screen generates a remarkably reproducible and characteristic profile of differential in vitro cellular sensitivity, or lack thereof, across the 60 different cell lines comprising the panel. Several investigational approaches to display, analysis, and interpretation of such profiles and databases, derived from the testing of tens of thousands of substances during the past 4–5 years since the NCI screen became fully operational, have been explored. A variety of useful, practical applications of the in vitro screen have become apparent. As these applications continue to evolve, they are proving to be complementary to diverse other anticancer screening and drug discovery strategies being developed or pursued elsewhere. Reviewed herein are some practical considerations and selected specific examples, particularly illustrating research applications of the NCI screen that may be more broadly applicable to the search for new anticancer drug development leads with novel profiles of antitumor activity and/or mechanisms of action. © 1995 Wiley‐Liss, Inc. This article is a US Government work and, as such, is in the public domain in the United States of America.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, in December 1992, MDA‐MB‐435 was added to the NCI‐60 cell line panel for use in anticancer drug screening, where it was initially described as a “breast” cancer cell line.17”
From Authentication of M14 melanoma cell line proves misidentification of MDA‐MB‐435 breast cancer cell line (2018) · cites this paper as [17]
Citations
Cites
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766
Self-citationMonks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Self-citationA Human Cell Line From a Pleural Effusion Derived From a Breast Carcinoma 2
Soule, H. D., Vazquez, J., Long, A., Albert, S., & Brennan, M. (1973) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/51.5.1409 · Cited by 2,449
Establishment and characterization of a human prostatic carcinoma cell line (PC-3).
Kaighn, M. E., Ks, N., Ohnuki, Y., Lechner, J. F., & Jones, L. W. (1979) · PubMed · Cited by 2,121
Breast Tumor Cell Lines From Pleural Effusions2
Cailleau, R., Young, R., Olivé, M., & Reeves, W. J. (1974) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/53.3.661 · Cited by 1,015
Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A., Scudiero, D. A., Rubinstein, L., Plowman, J., & Boyd, M. R. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.14.1088 · Cited by 967
Self-citationRubinstein, L. V., Shoemaker, R. H., Paull, K. D., Simon, R. M., Tosini, S., Skehan, P., Scudiero, D. A., Monks, A., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1113 · Cited by 927
Self-citationIsolation of a human prostate carcinoma cell line (DU 145)
Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H., & Paulson, D. F. (1978) · International Journal of Cancer · doi:10.1002/ijc.2910210305 · Cited by 926
Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization
Cailleau, R., Olivé, M., & Cruciger, Q. V. J. (1978) · In Vitro · doi:10.1007/bf02616120 · Cited by 679
Establishment and characterization of a cell line of human breast carcinoma origin
Keydar, I., Chen, L., Karby, S., Weiss, F. R., Delarea, J., Radu, M., Chaitcik, S., & Brenner, H. J. (1979) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(79)90139-7 · Cited by 650
Research works printed but not linked: 6
- Acton EM, 1992, Anticancer specificity of some ellipticinium salts against human brain tumors in vitro, Proc Am Assoc Cancer Res, 33, 488
- Boyd MR, 1986, Accomplishments in Oncology, Vol 1, Cancer Therapy: Where Do We Go From Here?, 68
- Boyd MR, 1989, Cancer: Principles and Practice of Oncology Updates, 1
- Buolamwini JK, 1994, Searching for new molecular targets for therapy of cancer and AIDS: Characterization by 2D protein gel electrophoresis, Proc Am Assoc Cancer Res, 35, 613
- Grever MR, 1994, Status of in vivo evaluations in the NCI anticancer drug discovery program, Proc Am Assoc Cancer Res, 35, 369
- Stinson SF, 1992, Morphologic and immunocytochemical characteristics of human tumor cell lines for use in an anticancer drug screen, Anticancer Res, 12, 1035
Cited by
Items 301–400 of 1,000
Gümüş, F., Pamuk, İ., ÖZDEN, T., Yıldız, S., Diril, N., Öksüzoğlu, E., Gür, S., & Özkul, A. (2003) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(03)00005-9 · Cited by 61
Synthesis and Anticancer and Antiviral Activities of New 2‐Pyrazoline‐Substituted 4‐Thiazolidinones
Havrylyuk, D., Zimenkovsky, B. S., Vasylenko, O., & Lesyk, R. (2013) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.1056 · Cited by 61
Negri, A., Marco, E., García-Hernández, V., Domingo, A., Llamas-Saiz, A. L., Porto-Sandá, S., Riguera, R., Laine, W., David‐Cordonnier, M., Bailly, C., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070381s · Cited by 60
Asymmetric Synthesis and Biological Properties of Uncialamycin and 26‐ epi ‐Uncialamycin
Nicolaou, K. C., Chen, J. S., Zhang, H., & Montero, A. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200704577 · Cited by 60
Synthesis of 5-enamine-4-thiazolidinone derivatives with trypanocidal and anticancer activity
Holota, S. M., Kryshchyshyn‐Dylevych, A., Derkach, H., Trufin, Y., Demchuk, I., Gzella, A. K., Grellier, P., & Lesyk, R. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.01.045 · Cited by 60
A Two‐Step Synthesis of Cytostatically Active Benzo[c]phenanthridine Derivatives
Clement, B., Weide, M., Wolschendorf, U., & Kock, I. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200461969 · Cited by 60
Abdel‐Aziz, A. A. ‐., El‐Azab, A. S., Alanazi, A. M., Asiri, Y. A., Al-Suwaidan, I. A., Maarouf, A. R., Ayyad, R. R. A., & Shawer, T. Z. (2015) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2015.1069288 · Cited by 59
Akihisa, T., Tokuda, H., Ichiishi, E., Mukainaka, T., Toriumi, M., Ukiya, M., Yasukawa, K., & Nishino, H. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00689-9 · Cited by 59
Cinelli, M. A., Reddy, P. V., Lv, P.-C., Liang, J., Chen, L., Agama, K., Pommier, Y. G., van Breemen, R. B., & Cushman, M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300519w · Cited by 59
Recent advances in synthesis and biological activity of triterpenic acylated oximes
Bednarczyk–Cwynar, B., & Zaprutko, L. (2014) · Phytochemistry Reviews · doi:10.1007/s11101-014-9353-5 · Cited by 59
Sayed, M. T. E., Hussein, H. A. R., El‐Ebiary, N. M. A., Hassan, G. S., El‐Messery, S. M., El‐Sheakh, A. R., Nayel, M., & Abdel‐Aziz, H. A. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.03.009 · Cited by 59
A novel bis-phenanthridine triamine with pH controlled binding to nucleotides and nucleic acids
Malojcic, G., Piantanida, I., Marinić, M., Žinić, M., Marjanović, M., Kralj, M., Pavelić, K., & Schneider, H. (2005) · Organic & Biomolecular Chemistry · doi:10.1039/b509094f · Cited by 59
Fadaly, W. A. A., Nemr, M. T. M., & Kahk, N. M. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107403 · Cited by 60
Slawinski, J. J., Szafrański, K., Vullo, D., & Supuran, C. T. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.09.027 · Cited by 58
Rostom, S. A. F., Faidallah, H. M., Radwan, M. F., & Badr, M. H. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.02.027 · Cited by 58
Suberosenone, a new cytotoxin from Subergorgia suberosa
Bokesch, H. R., McKee, T. C., Cardellina, J. H., & Boyd, M. R. (1996) · Tetrahedron Letters · doi:10.1016/0040-4039(96)00528-x · Cited by 58
Self-citationStarčević, K., Kralj, M., Piantanida, I., Šuman, L., Pavelić, K., & Karminski-Zamola, G. M. (2006) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2006.03.012 · Cited by 58
Alanazi, A. M., Abdel‐Aziz, A. A. ‐., Shawer, T. Z., Ayyad, R. R. A., Al-Obaid, A. M., Al-Agamy, M. H., Maarouf, A. R., & El‐Azab, A. S. (2015) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2015.1060482 · Cited by 57
Shaala, L. A., & Youssef, D. T. A. (2015) · Marine Drugs · doi:10.3390/md13041698 · Cited by 57
Covell, D. G., Huang, R., & Wallqvist, A. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0787 · Cited by 57
Rostom, S. A. F., Hassan, G. S., & El‐Subbagh, H. I. (2009) · Archiv der Pharmazie · doi:10.1002/ardp.200900062 · Cited by 57
Antifibrotic and anticancer action of 5-ene amino/iminothiazolidinones
Kaminskyy, D. V., den Hartog, G. J. M., Wojtyra, M., Lelyukh, M. I., Gzella, A. K., Bast, A., & Lesyk, R. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.02.011 · Cited by 60
Fahmy, H. H., Khalifa, N. M., Ismail, M. M. F., EL‐SAHRAWI, H. M., & Nossier, E. S. (2016) · Molecules · doi:10.3390/molecules21030271 · Cited by 57
Anderson, C. M., Taylor, I. R., Tibbetts, M. F., Philpott, J., Hu, Y., & Tanski, J. M. (2012) · Inorganic Chemistry · doi:10.1021/ic301981s · Cited by 57
Solano, B., Junnotula, V., Marín, A., Villar, R., Burguete, A., Vicente, E. F., Pérez‐Silanes, S., Aldana, I., Monge, A., Dutta, S., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0703993 · Cited by 57
Salmon, S. E., Liu-Stevens, R. H., Zhao, Y. Q., Lebl, M., Krchňák, V., Wertman, K., SEPETOV, N. F., & Lam, K. S. (1996) · Molecular Diversity · doi:10.1007/bf01718701 · Cited by 57
Ahsan, M. J., Choudhary, K., Jadav, S. S., Yasmin, S., Ansari, M. Y., & Sreenivasulu, R. (2015) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1457-y · Cited by 56
Lawal, B., Liu, Y., Mokgautsi, N., Khedkar, H., Sumitra, M. R., Wu, A. T. H., & Huang, H. (2021) · Biomedicines · doi:10.3390/biomedicines9010092 · Cited by 58
Novel synthesis of nicotinamide derivatives of cytotoxic properties
Girgis, A. S., Hosni, H. M., & Barsoum, F. F. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.02.031 · Cited by 56
El‐Messery, S. M., Hassan, G. S., Al-Omary, F. A. M., & El‐Subbagh, H. I. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.06.013 · Cited by 56
The effect of PLC-γ2 inhibitors on the growth of human tumour cells
Feng, L., Reynisdóttir, I., & Reynisson, J. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.05.029 · Cited by 58
Synthesis, Antimicrobial and Anticancer Activity of New Thiosemicarbazone Derivatives
Kulandaivelu, U., Padmini, V. G., Suneetha, K., Boyapati, S., Vidyasagar, J. V., Rao, T. R., Jayaveera, K. N., Basu, A., & Jayaprakash, V. (2010) · Archiv der Pharmazie · doi:10.1002/ardp.201000201 · Cited by 56
Patel, N. B., Purohit, A. C., Rajani, D. P., Moo-Puc, R. E., & Rivera, G. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.12.055 · Cited by 55
Structure–Activity Relationships of C-17 Cyano-Substituted Estratrienes as Anticancer Agents
Leese, M. P., Jourdan, F. L., Gaukroger, K., Mahon, M. F., Newman, S. P., Foster, P., Stengel, C., Regis-Lydi, S., Ferrandis, E., Fiore, A. D., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701319c · Cited by 60
El‐Subbagh, H. I., Hassan, G. S., El‐Messery, S. M., Al‐Rashood, S. T., Al-Omary, F. A. M., Abulfadl, Y. S., & Shabayek, M. I. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.004 · Cited by 55
Synthesis and Anticancer Activity of New Thiopyrano[2,3-d]thiazoles Based on Cinnamic Acid Amides
Lozynskyi, A., Zimenkovsky, B., & Lesyk, R. (2014) · Scientia Pharmaceutica · doi:10.3797/scipharm.1408-05 · Cited by 55
Preclinical screening methods in cancer
Bodla, R. B., Kumar, S., & Bajaj, S. (2016) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.190716 · Cited by 60
Sequoiamonascins A−D: Novel Anticancer Metabolites Isolated from a Redwood Endophyte
Stierle, D. B., Stierle, A. A., & Bugni, T. S. (2003) · The Journal of Organic Chemistry · doi:10.1021/jo0340253 · Cited by 55
Selective synthesis of (Z)-4-aryl-5-[1-(aryl)methylidene]-3-bromo-2(5H)-furanones
Bellina, F., Anselmi, C., Viel, S., Mannina, L., & Rossi, R. (2001) · Tetrahedron · doi:10.1016/s0040-4020(01)01017-1 · Cited by 55
Guo, C., Bhandaru, S., Fuchs, P. L., & Boyd, M. R. (1996) · Journal of the American Chemical Society · doi:10.1021/ja962646q · Cited by 55
Self-citationKorch, C., Hall, E. M., Dirks, W. G., Ewing, M., Faries, M., Varella‐Garcia, M., Robinson, S., Storts, D., Turner, J. A., Wang, Y., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31067 · Cited by 54
“For example, in December 1992, MDA-MB-435 was added to the NCI-60 cell line panel for use in anticancer drug screening, where it was initially described as a “breast” cancer cell line.(17) STR profiling of the NCI-60 panel later confirmed the shared donor origin of these cells with M14.”
MethodLawal, B., Lee, C., Mokgautsi, N., Sumitra, M. R., Khedkar, H., Wu, A. T. H., & Huang, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.656738 · Cited by 54
Kamal, Ä., Rao, A., Nayak, V., Reddy, N. V. S., Swapna, K., Ramakrishna, G., & Alvala, M. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob01930j · Cited by 55
Kohn, L. K., Pavam, C. H., Veronese, D., Coelho, F., de Carvalho, J. E., & Almeida, W. P. (2006) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2006.03.006 · Cited by 54
Alaklabi, A., Arif, I. A., Ahamed, A., Surendrakumar, R., & Idhayadhulla, A. (2017) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2016.12.021 · Cited by 54
Elsayed, N. M. Y., Serya, R. A. T., Tolba, M. F., Ahmed, M., Barakat, K., Ella, D. A. A. E., & Abouzid, K. A. M. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.10.071 · Cited by 56
One-pot three-component synthesis of novel pyrazolo[3,4-b]pyridines as potent antileukemic agents
Barghash, R. F., Eldehna, W. M., Kovalová, M., Vojáčková, V., Kryštof, V., & Abdel‐Aziz, H. A. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113952 · Cited by 56
Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines
Rivera, M. I., Stinson, S. F., Vistica, D. T., Jorden, J. L., Kenney, S., & Sausville, E. A. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00046-5 · Cited by 54
González, J. F., de la Cuesta, E., & Avendaño, C. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.10.009 · Cited by 54
New bis(pyridyl)methane derivatives from 4-hydroxy-2-pyridones: synthesis and antitumoral activity
Cocco, M. T., Congiu, C., & Onnis, V. (2003) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(02)00002-8 · Cited by 54
Edsall, A. B., Mohanakrishnan, A. K., Yang, D., Fanwick, P. E., Hamel, E., Hanson, A. D., Agoston, G. E., & Cushman, M. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049647a · Cited by 54
Identifying genes related to drug anticancer mechanisms using support vector machine
Bao, L., & Sun, Z. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02835-1 · Cited by 54
Kassab, A. E., & Gedawy, E. M. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.02.011 · Cited by 53
Tetrazolylmethyl quinolines: Design, docking studies, synthesis, anticancer and antifungal analyses
Shaikh, S. K. J., Kamble, R. R., Somagond, S. M., DEVARAJEGOWDA, H. C., Dixit, S. R., & Joshi, S. D. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.01.043 · Cited by 54
Selective Cytotoxicity Evaluation in Anticancer Drug Screening of Fractionated Plant Extracts
Lindholm, P., Gullbo, J., Claeson, P., Göransson, U., Johansson, S., Backlund, A., Larsson, R. L., & Bohlin, L. (2002) · SLAS DISCOVERY · doi:10.1177/108705710200700405 · Cited by 53
Dallemagne, P., Khanh, L. P., ALSAIDI, A., Varlet, I., Collot, V., Paillet, M., Bureau, R., & Rault, S. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00654-5 · Cited by 53
Synthesis and antineoplastic activity of 2-alkylaminoethyl derivatives of various steroidal oximes
Jindal, D. P., Chattopadhaya, R., Guleria, S., & Gupta, R. (2003) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2003.09.002 · Cited by 52
Fadaly, W. A. A., Elshaier, Y. A. M. M., Nemr, M. T. M., & Abdellatif, K. R. A. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106428 · Cited by 52
Synthesis and Anticancer Activity of Novel Nonfused Bicyclic Thiazolidinone Derivatives
Havrylyuk, D., Zimenkovsky, B. S., & Lesyk, R. (2009) · Phosphorus, sulfur, and silicon and the related elements · doi:10.1080/10426500802247563 · Cited by 52
Synthesis and Biological Evaluation of ABCD Ring Fragments of the Kibdelones
Sloman, D. L., Mitasev, B., Scully, S. S., Beutler, J. A., & Porco, J. A. J. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201007613 · Cited by 52
González‐Vallinas, M., Molina, S., Vicente, G., Sánchez‐Martínez, R., Vargas, T., García‐Risco, M. R., Fornari, T., Reglero, G., & de Molina, A. R. (2014) · Electrophoresis · doi:10.1002/elps.201400011 · Cited by 59
Das, S., Das, U., Selvakumar, P., Sharma, R. K., Balzarini, J. M., Clercq, E. D., Molnar, J. A., Serly, J., Baráth, Z., Schatte, G., et al. (2009) · ChemMedChem · doi:10.1002/cmdc.200900288 · Cited by 52
Identification of a New Chondropsin Class of Antitumor Compound That Selectively Inhibits V-ATPases
Bowman, E. J., Gustafson, K. R., Bowman, B. J., & Boyd, M. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306595200 · Cited by 60
Self-citationKandeel, M. M., Refaat, H. M., Kassab, A. E., Shahin, I. G., & Abdelghany, T. M. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.12.009 · Cited by 51
Determann, R., Dreher, J., Baumann, K., Preu, L., Jones, P. G., Totzke, F., Schächtele, C., Kubbutat, M. H. G., & Kunick, C. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.04.007 · Cited by 51
Pederson, P. J., Mfuh, A. M., Arman, H. D., Shaffer, C. V., Larionov, O. V., & Mooberry, S. L. (2017) · Journal of Natural Products · doi:10.1021/acs.jnatprod.6b00963 · Cited by 51
Husseiny, E. M. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104053 · Cited by 51
Joo, S., Kim, M. S., Yang, J., & Park, J. (2020) · ACS Omega · doi:10.1021/acsomega.0c01149 · Cited by 59
Cytotoxicity of three cycloartane triterpenoids from Cimicifuga dahurica
Tian, Z., Yang, M., Huang, F., Li, K., Si, J., Shi, L., Chen, S., & Xiao, P. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.11.019 · Cited by 51
Rathore, P., Yaseen, S., Ovais, S., Bashir, R., Yaseen, R., Hameed, A. D., Samim, M., Gupta, R. K., Hussain, F., & Javed, K. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.02.059 · Cited by 51
Synthesis and in vitro cytotoxic effect of 6-amino-substituted 11H- and 11Me-indolo[3,2-c]quinolines
Wang, N., Świtalska, M., Wu, M., Imai, K., Ngoc, T. A., Pang, C., Wang, L., Wietrzyk, J., & Inokuchi, T. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.03.038 · Cited by 51
Al-Omary, F. A. M., Hassan, G. S., El‐Messery, S. M., Nagi, M. N., Habib, E. E., & El‐Subbagh, H. I. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.12.061 · Cited by 51
Khalil, A. A., Abdel‐Hamide, S. G., Al-Obaid, A. M., & El‐Subbagh, H. I. (2003) · Archiv der Pharmazie · doi:10.1002/ardp.200390011 · Cited by 51
Wallqvist, A., Rabow, A. A., Shoemaker, R. H., Sausville, E. A., & Covell, D. G. (2002) · PubMed · Cited by 51
Voskoboynik, О. Y., Starosyla, S. A., Protopopo, M. V., Hp, V., Shyshkina, S. V., Yarmoliuk, S. M., & Коваленко, С. І. (2016) · Medical and Clinical Chemistry · doi:10.11603/mcch.2410-681x.2016.v0.i1.6123 · Cited by 50
A synthesis, in silico, in vitro and in vivo study of thieno[2,3-b]pyridine anticancer analogues
Arabshahi, H. J., van Rensburg, M., Pilkington, L. I., Jeon, C. Y., Song, M., Gridel, L.-M., Leung, E. Y., Barker, D. L. A., Vuica‐Ross, M., Volcho, K. P., et al. (2015) · MedChemComm · doi:10.1039/c5md00245a · Cited by 50
Hafez, T. S., Osman, S. A., Yosef, H. A. A., El‐All, A. S. A., Hassan, A. S., El-Sawy, A. A., ABDALLAH, M. I., & Youns, M. (2013) · Scientia Pharmaceutica · doi:10.3797/scipharm.1211-07 · Cited by 50
Azole‐Based Cyclic Peptides from the Sea Squirt Lissoclinum Patella: Old Scaffolds, New Avenues
Houssen, W. E., & Jaspars, M. (2010) · ChemBioChem · doi:10.1002/cbic.201000230 · Cited by 60
Bioactive Secondary Metabolites from the Red Sea Marine Verongid Sponge Suberea Species
Shaala, L. A., Youssef, D. T. A., Badr, J. M., Sulaiman, M. I., & Khedr, A. (2015) · Marine Drugs · doi:10.3390/md13041621 · Cited by 50
Slator, C., Barron, N., Howe, O. L., & Kellett, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00513 · Cited by 52
Abdel‐Aziz, A. A. ‐., El‐Azab, A. S., El‐Subbagh, H. I., Al-Obaid, A. M., Alanazi, A. M., & Al-Omar, M. A. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.01.036 · Cited by 50
Perron, V., Rabouin, D., Asselin, É., Parent, S., Gaudreault, R. C., & Bérubé, G. (2004) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2004.06.009 · Cited by 50
Kamal, A., Kumar, B., Arifuddin, M., & Dastidar, S. G. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2003.08.019 · Cited by 49
Ahsan, M. J., Khalilullah, H., Yasmin, S., Jadav, S. S., & Jeyabalan, G. (2013) · BioMed Research International · doi:10.1155/2013/239354 · Cited by 49
Component-based syntheses of trioxacarcin A, DC-45-A1 and structural analogues
Magauer, T., Smaltz, D. J., & Myers, A. G. (2013) · Nature Chemistry · doi:10.1038/nchem.1746 · Cited by 49
Zhang, L., Chen, X., Guan, N., Liu, H., & Li, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01017 · Cited by 54
Isolation of Cytotoxic Metabolites from Targeted Peruvian Amazonian Medicinal Plants
Aponte, J. C., Vaisberg, A., Rojas, R., Caviedes, L., Lewis, W. H., Lamas, G. L., Sarasara, C., Gilman, R. H., & Hammond, G. B. (2007) · Journal of Natural Products · doi:10.1021/np070560c · Cited by 49
A New Staurosporine Analog from the Prosobranch MolluskCoriocella Nigra
Cantrell, C. L., Groweiss, A., Gustafson, K. R., & Boyd, M. R. (1999) · Natural product letters · doi:10.1080/10575639908045433 · Cited by 49
Self-citationMorrell, A. E., Antony, S., Kohlhagen, G., Pommier, Y. G., & Cushman, M. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.01.008 · Cited by 49
Sreerama, L., & Sládek, N. E. (1996) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-5871-2_11 · Cited by 49
Chew, E., Lu, J., Bradshaw, T. D., & Holmgren, A. (2008) · The FASEB Journal · doi:10.1096/fj.07-101477 · Cited by 53
Imidazopyridine-fused [1,3]-diazepinones: Synthesis and antiproliferative activity
Gallud, A., Vaillant, O., Maillard, L. T., Arama, D. P., Dubois, J., Maynadier, M., Lisowski, V., Garcia, M., Martínez, J., & Masurier, N. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.044 · Cited by 48
Nemr, M. T. M., Sonousi, A. S. M., & Marzouk, A. A. E. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104446 · Cited by 48
Bioactive Compounds from Marine Heterobranchs
Àvila, C., & Angulo‐Preckler, C. (2020) · Marine Drugs · doi:10.3390/md18120657 · Cited by 51
Strategies in the Search for New Lead Compounds or Original Working Hypotheses
Wermuth, C. G., Villoutreix, B. O., Grisoni, S., Olivier, A., & Rocher, J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00004-3 · Cited by 55
Ubiquitin proteasome pathway: implications and advances in cancer therapy
Shah, S. A., Potter, M. W., & Callery, M. P. (2001) · Surgical Oncology · doi:10.1016/s0960-7404(01)00018-4 · Cited by 52
Sequoiatones A and B: Novel Antitumor Metabolites Isolated from a Redwood Endophyte
Stierle, A. A., Stierle, D. B., & Bugni, T. S. (1999) · The Journal of Organic Chemistry · doi:10.1021/jo990277l · Cited by 48
Fourier Ptychographic Microscopy 10 Years on: A Review
Xu, F., Wu, Z., Tan, C., Liao, Y., Wang, Z., Chen, K., & Pan, A. (2024) · Cells · doi:10.3390/cells13040324 · Cited by 47
Берест, Г. Г., Воскобойнік, О. Ю., Коваленко, С. І., Antypenko, O., Носуленко, И. С., Katsev, A. M., & Shandrovskaya, O. S. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.10.022 · Cited by 47
Synthesis and in vitro antitumoral activity of new 3,5-dicyanopyridine derivatives
Cocco, M. T., Congiu, C., Lilliu, V., & Onnis, V. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.11.031 · Cited by 48
Metadata
- Authors
- Boyd, M. R., & Paull, K. D.
- Affiliations
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (US)
- Corresponding author
- Boyd, Michael R.
- ORCID
- Boyd, Michael R.
- Venue
- Drug Development Research
- Publisher
- Wiley
- Published
- 1995-02
- Volume
- 34
- Issue
- 2
- Pages
- 91-109
- ISSN
- 0272-4391 (ISSN-L)
- 1098-2299
- OpenAlex
- W2118909720
- Cited by
- 1,572
- References
- 40
- Citations by year
- 2026: 28 · 2025: 57 · 2024: 79 · 2023: 58 · 2022: 68 · 2021: 81 · 2020: 74 · 2019: 51 · 2018: 58 · 2017: 39 · 2016: 56 · 2015: 61 · 2014: 78 · 2013: 84 · 2012: 79
- FWCI
- 30.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Development Research (publishedVersion, public-domain)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- anticancer drug discovery, human cancer cell lines, anticancer activity, lead compound identification, mechanism of action
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.